Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Narrative Review of Cannabidiol as an Antipsychotic and Recommendations for Legal Regulations

Walkey, Lisa Rachel Lena, BEng, MASc, MD; Tanguay, Robert L., BSc (Hons), MD, FRCPC, CCSAM, CISAM; el-Guebaly, Nady, MD, FRCPC, DABAM

Erratum

In the article that appeared on pages 23–29 of the Canadian Journal of Addiction September 2018 issue, 1 the disclosures of Robert Tanguay were not provided in the journal, and they are:

• Relationships with financial interests:

Grants/Research Support: Canopy, Otsuka, Pfizer, Perdue, Shire, Jansen, Sunovion, Lundbeck, Allergan

Speakers Bureau/Honoraria: Indivior, Canopy, Pfizer, Otsuka, Lundbeck

Consulting Fees: Lundbeck, Indivior, Allergan

Other: Independent CME - MD Briefcase Independent CME; Owner- RLT Conferences; Private- PFSP, CPSA, ABVMA, City of Calgary, Gov’t of Ab, ASEBP, Shell, Insurance Companies, Law Firms

The omission was not discovered until after the article published in the issue. The journal regrets this error.

Canadian Journal of Addiction. 9(4):24, December 2018.

doi: 10.1097/CXA.0000000000000026
REVIEW ARTICLE
Buy
Erratum

ABSTRACT Introduction:

This paper will review the effects of cannabidiol (CBD) in regards to psychosis and schizophrenia, and its purported treatment for psychosis.

Methods:

A PubMed search was completed using terms: "Cannabidiol and Psychosis," for which 63 studies were found; "Cannabidiol and Schizophrenia," for which 65 studies were found; and "Cannabidiol and Psychotomimetic," for which 37 studies were found. Inclusion criteria included English-language articles published from 2000 to present (July 2016) for human studies only, leading to 7 clinical trials for review. Following this search, 2 additional papers published in 2018 were added for completeness, totaling 9 clinical trials.

Results:

There have been recent studies showing psychosis is secondary to the tetrahydrocannabinol (THC) in marijuana; more striking is that studies were found showing CBD may be protective and actually have antipsychotic properties equal in efficacy to atypical antipsychotics. THC and CBD seem to have opposite physiologic effects on endogenous anandamide levels and cannabinol receptor binding, the mechanism likely leading to CBD's antipsychotic effect.

Conclusions:

Early evidence shows that CBD may be a novel and viable treatment for psychosis. This may have an effect on the regulation of CBD and THC percentages in regards to the prevention of early onset schizophrenia.

University of Calgary, Calgary, Alberta

Corresponding Author: Lisa Rachel Lena Walkey, BEng, MASc, MD, University of Calgary, Calgary, Alberta, Canada. E-mail: lrlhunt@gmail.com

The authors report no conflicts of interest.

Received February 26, 2018

Accepted June 29, 2018

© 2018 by Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website